Erythropoietin Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Erythropoietin Drugs Market was valued at approximately USD 10.4 billion in 2023 and is projected to grow at a CAGR of 4.5% from 2024 to 2032. Erythropoietin drugs stimulate the body's production of red blood cells (RBCs). They replicate the function of erythropoietin, a hormone from the kidneys that governs RBC production. These medications primarily address anemia, a condition marked by a shortage of red blood cells.

The market is significantly driven by the rising cancer prevalence. The World Health Organization (WHO) reported an estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. This highlights the surging demand for erythropoietin drugs, pivotal in managing treatment-related anemia, thereby enhancing patient outcomes and life quality.

Innovations in erythropoietin drug formulations have revolutionized anemia management. These advancements prioritize boosting efficacy for ensuring safety and enhancing patient convenience in erythropoietin therapies. Recent formulations, like the extended-release versions of erythropoietin drugs, enable less frequent dosing. For instance, darbepoetin-alfa's extended half-life allows injections to be spaced out from the previous weekly schedule to once every two or three weeks.

The erythropoietin drugs industry is divided into drug type, drug class, application, distribution channel, and region.

The market categorizes drug types into biosimilars, first-generation formulations, and second-generation formulations. Projections indicate that the biosimilars segment will hit USD 7 billion by 2032. Biosimilars generally come at a lower price than their reference biologics. This price advantage makes erythropoietin therapies more accessible, especially in regions with constrained resources or elevated healthcare expenses. Offering a budget-friendly alternative, biosimilars broaden patient access to vital anemia treatments, especially for those previously unable to afford the original biologic drugs.

The market segments drug classes into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. In 2023, the epoetin-alfa segment generated USD 3.7 billion. Epoetin-alfa is adept at stimulating erythropoiesis (RBC production) in the bone marrow, making it a prime choice for anemia linked to chronic kidney disease (CKD), cancer chemotherapy, and other ailments. By enhancing RBC production, epoetin-alfa diminishes or negates the necessity for blood transfusions, which carry risks like transfusion reactions and infections.

U.S. erythropoietin drugs market size will touch USD 5.8 billion by 2032. The U.S. is home to a cutting-edge healthcare system, equipped with modern medical facilities and technologies for ensuring optimal management of erythropoietin drugs. In 2020, the Centers for Disease Control and Prevention (CDC) recorded 1,603,844 new cancer cases in the U.S., with the disease claiming 602,347 lives.

Product Code: 10624

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of chronic kidney disease (CKD)
  - 3.2.1.2 Advancements in drug formulations
  - 3.2.1.3 Increasing incidence of cancer
  - 3.2.1.4 Rising geriatric population
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of drugs
  - 3.2.2.2 Potential side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Pricing analysis
- 3.6.1 By region
- 3.6.2 By key player
3.7 Future market trends
3.8 Pipeline analysis
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Biosimilars
5.3 First-generation formulation
5.4 Second-generation formulation

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Epoetin-alfa
6.3 Epoetin-beta
6.4 Darbepoetin-alfa
6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cancer
7.3 Renal diseases
7.4 Neurology
7.5 Hematology
7.6 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 AstraZeneca PLC
10.2 Amgen, Inc.
10.3 Biocon Limited
10.4 Celltrion, Inc.
10.5 Dr. Reddy's Laboratories Ltd.
10.6 F. Hoffmann-La Roche Ltd.
10.7 Intas Pharmaceuticals Ltd.
10.8 Johnson and Johnson
10.9 Kyowa Kirin Co., Ltd.
10.10 LG Chem, Ltd.
10.11 Novartis AG
10.12 Pfizer Inc.
10.13 Sanofi
10.14 Sun Pharmaceutical Industries Ltd.
10.15 Teva Pharmaceutical Industries Ltd.